Seeking Alpha

MEI Pharma gets a lift from positive initiation at Brean

  • Brean starts MEI Pharma (MEIP +5%) at Buy, citing "Pracinostat’s expected peak revenue of $700M in two indications, MDS and AML."
  • With several Phase 2 trials in the works, analyst Gene Mack sees "the commercial launch of Pracinostat in 2017/2018 contributing $12/share to valuation."
  • Price target is $16, representing upside of ~104% from Thursday's close.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: